Who
Dennis Langer
Director
Company insider
Files Form 4 as: Director, Quoin Pharmaceuticals; Director, Myriad Genetics; Director, Ernexa Therapeutics; Director, Dicerna Pharmaceuticals; Director, Pernix Therapeutics Holdings; Director, Delcath Systems; Director, Myrexis; Director, Auxilium Pharmaceuticals.
In numbers
- Trades disclosed
- 194
- Buys
- 1
- Sells
- 19
- Bought
- $129K
- Sold
- $10.6M
- Companies
- 11
- Companies where not an officer
- 11
- First trade
- 6 Jan 2006
- Last trade
- 27 Aug 2026
- Last filed
- 28 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Aug 2026filed 28 Aug 2026 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $178K34,534 at $5.15 | filing |
| 27 Aug 2026filed 28 Aug 2026 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $178K34,534 at $5.15 | filing |
| 4 Feb 2026filed 6 Feb 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,709 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,709 at $0.00 | filing |
| 14 Oct 2025filed 15 Oct 2025 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —15,152 | filing |
| 14 Oct 2025filed 15 Oct 2025 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —15,152 | filing |
| 14 Oct 2025filed 15 Oct 2025 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —15,152 | filing |
| 14 Oct 2025filed 15 Oct 2025 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —15,152 | filing |
| 14 Oct 2025filed 15 Oct 2025 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $129K15,152 at $8.49 | filing |
| 21 Aug 2025filed 25 Aug 2025 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,682 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,760 at $0.00 | filing |
| 9 Dec 2024filed 10 Dec 2024 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,714 at $0.00 | filing |
| 7 Jun 2024filed 10 Jun 2024 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $217297 at $0.73 | filing |
| 26 Oct 2023filed 30 Oct 2023 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,652 at $0.00 | filing |
| 2 Jun 2022filed 3 Jun 2022 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —17,275 at $0.00 | filing |
| 8 Dec 2021filed 10 Dec 2021 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 3 Aug 2021filed 5 Aug 2021 | MYGN Myriad Geneticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 3 Aug 2021filed 5 Aug 2021 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code M | $762K30,000 at $25.39 | filing |
| 3 Aug 2021filed 5 Aug 2021 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Sold | $1.0M30,000 at $34.75 | filing |
| 3 Jun 2021filed 4 Jun 2021 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —12,848 at $0.00 | filing |
News
Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)MYGN · tickerreport.com · 20 Oct 2026Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing BusinessMYGN · investorideas.com · 20 Oct 2026FinancialContent - Myriad Genetics (MYGN) Stock Trades Up, Here Is WhyMYGN · financialcontent.com · 20 Oct 2026Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Rating Raised to "Sell" at Wall Street ZenQNRX · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Dennis Langer; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.